Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 Infection
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is:
1. To assess the antiviral activity of PRO 140
2. To assess the safety and tolerability of PRO 140
3. To generate additional PK, PD and safety data of PRO 140
Phase:
Phase 2
Details
Lead Sponsor:
CytoDyn, Inc.
Treatments:
Antibodies Antibodies, Monoclonal HIV Antibodies Leronlimab PRO-140 monoclonal antibody